Search bioRxiv⌕ Search

bioRxiv · 10.1101/2024.10.08.617273

Validation of DoriVac (DNA origami vaccine) efficacy in a metastatic melanoma model

Abstract

Metastatic cancer, particularly metastatic melanoma, poses a significant therapeutic challenge due to its resistance to standard treatments and low five-year survival rate of 20-27%. Current therapies show limited success, highlighting the urgent need for novel interventions. Recent advances in cancer vaccine research show great promise in reducing disease recurrence, but these approaches still face challenges pertaining to antigen selection, ease of production, and programmability. To address some of these challenges, we have adapted the DoriVac platform to serve as a cancer vaccine against metastatic melanoma. DoriVac is a DNA origami-based vaccine platform that allows for the codelivery of antigens of choice and the CpG immune adjuvant at an optimal nanospacing to promote Th1 immune polarization. In our study, we observed a significant reduction in lung tumor nodules for mice treated with DoriVac in both the B16OVA and B16F10 melanoma mouse models. DoriVac also appears to be a safe and effective treatment, with no anti-drug antibodies, as indicated by lower anti-dsDNA levels. Importantly, we observed an amplified effect when DoriVac was combined with PD-L1 immune checkpoint blockade, leading to an even greater reduction in metastatic lung tumor nodules. Our results also indicate an increased activation of antigen presenting cells, NK cells, CD4+ T cells and CD8+ T cells. These findings suggest that DoriVac, particularly in combination with the PD-L1 immune checkpoint blockade, can serve as a promising immunotherapy against metastatic cancer.

Source connections

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Rajwar, A., Dembele, H., Graveline, A., Vernet, A., Sanchez, M., Bardales, S., Kwon, I. C., Ryu, J. H., Shih, W. M., Zeng, Y. C.. 2024-10-08. Validation of DoriVac (DNA origami vaccine) efficacy in a metastatic melanoma model. https://doi.org/10.1101/2024.10.08.617273

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Minimal, synthetic arginine deiminase pathway provides full ATP demand for cellular growth

Bottom-up construction of synthetic cells requires a simple, yet robust ATP-generating system. The arginine deiminase (ADI) pathway offers a minimal, enzyme-based alternative to more complex ATP-producing systems such as glycolytic routes, respiratory chains or photosystems. Here, we implement the ADI pathway in Escherichia coli and test its capacity to fully replace native ATP generation. First, we designed and tested synthetic ADI operons through combinatorial library screening and selected high-performing variants. Using the best performing-ADI variant, we progressively reduced the cells dependence on native ATP generation while increasing selection for ADI-dependent growth through targeted knockout strains and growth conditions, followed by adaptive laboratory evolution. This resulted in a strain in which the ADI pathway sustained growth in minimal medium at a doubling time of 21 hours, serving as the sole source of ATP. Whole-genome sequencing of evolved strains revealed that this transition required loss-of-function mutations in the native respiratory chain. These findings demonstrate that the ATP supply of a cell can be fully supported by the ADI pathway, which has not been demonstrated in nature. Moreover, the ability of the pathway to sustain growth with a relatively high growth rate highlights its potential to fully power synthetic cells and support other biotechnological applications.

synthetic biology↗

Scalable recorders of cellular calcium dynamics and molecular interactions across time

Cellular processes are mediated by dynamic biochemical events in their native context, including changes in intracellular ion concentrations and transient interactions between molecules. Studying these processes across large cell populations requires recording their dynamics across time in single cells, simultaneously and at scale. Here, we introduce split-1POK, a split protein tape monomer whose two halves reconstitute when the domains fused to them interact. The reconstituted monomer is incorporated into the protein tape as it elongates across time in live cells, enabling scalable, spatiotemporally resolved endpoint readout under conventional light microscopy. Split-1POK provides a programmable scaffold for new recorders in the CytoSense family, our previously introduced framework (ref. 1) in which the same cytosol-localized monomer senses cellular activity and writes it along protein tape recorders. Unlike transcription-based activity recorders, which encode the signal through new gene expression, CytoSense recorders act on monomers post-synthesis, so the activity signal is sensed and written directly in the cytosol without passing through transcription- or translation-associated cascades. Fusing calmodulin and its binding peptide to split-1POK, we built TCaMP (Tape monomer-CalModulin-Peptide), a genetically encoded calcium recorder (GECR) that measures calcium dynamics on a single, analog intensity scale along a continuous time axis, providing quantitative comparison of calcium levels over time within the same cell. In cultured human cells, TCaMP records transient calcium dynamics from transmembrane entry, receptor activation, and intracellular store release, detecting stimulations as brief as ten minutes. With hour-scale kinetics over days, TCaMP complements fluorescent calcium indicators by trading sub-second temporal resolution for scalable, long-term recording. Fusing conditional dimerization pairs to split-1POK yields recorders of molecular interaction histories in response to external stimuli. Split-1POK thus brings scalable, spatiotemporally resolved recording to intracellular calcium dynamics and molecular interactions across time.

synthetic biology↗

Antibody design across observed and forecasted antigenic evolution

The therapeutic efficacy of antibodies is often limited by the evolution of their targets. Designing or eliciting antibodies that withstand such evolution is challenging as their binding interfaces must accommodate antigenic variation. Here, we introduce Germinal Multi, a computational framework for de novo antibody design and rescue that jointly optimizes a single paratope against multiple antigenic variants. We applied Germinal Multi to cancer and viral antigens, targeting both observed antigenic variation and prospective antibody escape. Multi-target optimization yielded antibodies that bound resistance-associated EGFR variants or that neutralized antigenically distinct historical SARS-CoV-2 variants, with recognition extending to variants withheld from the design process. Beyond acting on observed evolution, we redesigned the broadly neutralizing antibody BD55-1205 to restore neutralization of a prospective escape variant engineered with guidance from an evolutionary forecasting model, while preserving activity against the parental variant. Successful candidates were identified after screening tens of designs per campaign. Together, these results establish multi-target computational design as a strategy for generating antibody breadth across observed antigenic variation and demonstrate the potential of evolutionary forecasting to guide antibody redesign against prospective escape.

synthetic biology↗